Search results
Results from the WOW.Com Content Network
Over the years, the JPO has continued to amend these guidelines to clarify their application to new technologies. These amendments have broadened the scope of patents within the biotechnology industry. The Japanese Patent Act requires that patented inventions be “industrially applicable”, i.e. they must have market or commercial potential ...
Diamond v. Chakrabarty, 447 U.S. 303 (1980), was a United States Supreme Court case dealing with whether living organisms can be patented.Writing for a five-justice majority, Chief Justice Warren E. Burger held that human-made bacteria could be patented under the patent laws of the United States because such an invention constituted a "manufacture" or "composition of matter".
Bioethics and Patent Law: The Cases of Moore and the Hagahai People by Anja von der Ropp and Tony Taubman, WIPO Magazine, September 2006. "An Examination of the Issues Surrounding Biotechnology Patenting and its Effect Upon Entrepreneurial Companies", United States Congressional Research Service, August 31, 2000
United States biotechnology case law (13 P) This page was last edited on 26 April 2014, at 21:16 (UTC). Text is available under the Creative Commons Attribution ...
Pages in category "United States biotechnology case law" The following 13 pages are in this category, out of 13 total. This list may not reflect recent changes. A.
One application is the creation of enhanced seeds that resist extreme environmental conditions of arid regions, which is related to the innovation, creation of agriculture techniques and management of resources. [35] Violet biotechnology is related to law, ethical and philosophical issues around biotechnology. [35]
United States biotechnology law (1 C, 10 P) V. Vaccination law (1 C, 14 P, 1 F) Pages in category "Biotechnology law"
Mayo v. Prometheus, 566 U.S. 66 (2012), was a case decided by the Supreme Court of the United States that unanimously held that claims directed to a method of giving a drug to a patient, measuring metabolites of that drug, and with a known threshold for efficacy in mind, deciding whether to increase or decrease the dosage of the drug, were not patent-eligible subject matter.